In recent years, increased complexity in drug development has resulted in fewer products coming to market. The Critical Path Initiative suggests a re-evaluation of conventional business processes and a focus on information technology (IT) as an enabler. One factor is consistent—the need for business-critical information within IT systems agile enough to conform to the evolving business process requirements. From data mining and predictive modeling to manufacturing quality systems, an agile, robust IT infrastructure will allow the life sciences industry to achieve many of the goals set forth by the Critical Path Initiative.
As the life sciences industry begins to improve business processes to address its myriad challenges, access to credible and relevant business information is critical and will lead to increasing data integration efficiency from preclinical and early stage discovery. Many of the data integration challenges in drug discovery are a result of fast-paced advancement in both science and technology over the last couple decades. The advent of automated gene sequencing, expression analysis, combinatorial chemistry, and ultra-high throughput screening has contributed to the complexity of data integration. Although many good integration strategies exist, interest has shifted from physical data integration to new approaches, techniques, methods, and algorithms for performing semantic data integration.
Additionally, one of the most advanced areas in which IT can certainly improve the efficiency of discovery is in systems biology, which involves using complex analytical techniques to find novel patterns and insights. The life sciences industry is using IT to help generate new insights, making discovery more effective. Further, systems biology and the Semantic Web support the translational research approach indicated in the Critical Path Initiative.
As these technologies address the needs within discovery, similar interoperability requirements exist for clinical development. The integration of patient clinical information from clinical investigator sites and sponsors has the potential to advance the overall clinical development process and improve the likelihood for success. Here, the life sciences industry must work with IT providers to develop solutions using an industry standards-based approach (e.g., HL7 V3) as part of an overall electronic medical record. The integration and accessibility of patient clinical information and clinical trial management systems will serve as an important component in closing the gap between laboratory bench discovery and bedside application.
In addition to enabling patient-centric clinical information, IT solutions must also integrate with manufacturing processes to ensure the delivery of high-quality medical products. Improving manufacturing efficiencies, the third area of focus of the Critical Path Initiative, will require flexible and agile solutions that can easily adapt to the latest quality systems requirements. These IT solutions must go beyond conventional supply chain management requirements to automate a variety of compliance needs and provide critical information that enables more effective business decisions. The implementation of product data hubs will play an important role in enabling life sciences companies to provide safe, effective medical products in a more timely and cost effective way.